An interventional study of Mobile phone-assisted intervention and Peer navigator in Opioid Use Disorder, sponsored by Johns Hopkins University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Supportive care
Among 41 studies in Opioid-Related Disorders by Johns Hopkins University — 4 open to participants now, 5 under way, none of them phase 3. Opioid-Related Disorders · Johns Hopkins University.
Among the 41 studies in Opioid-Related Disorders by Johns Hopkins University, this one is the 15th largest by planned enrollment of the 39 interventional ones, is one of 2 that started in 2027, is one of 16 with no phase, and was the 41st registered.
1,472 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.
This study's planned enrollment of 90 is above the median of 63 across 1,166 interventional studies indexed under Opioid-Related Disorders.
Browse Opioid-Related Disorders studies →4 of the 41 studies in Opioid-Related Disorders by Johns Hopkins University are open now, in 1 country. Each count lists the studies.
Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →41 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2027.
Median enrollment 76 across the 39 interventional studies, 89 across the 2 observational. Of the 34 that completed or were terminated, 18 (53%) have results posted.
Johns Hopkins University is the lead sponsor of 1,815 studies on the registry; 315 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
1 of the studies in Opioid-Related Disorders by Johns Hopkins University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05548582Johns Hopkins UniversityReduced Opioid Prescription After Laparoscopic Hysterectomy | 2026-12-31 |
Among the 41 studies in Opioid-Related Disorders by Johns Hopkins University, from their registry updates:
This is the third phase of the mPeer4Life study - the Trial Phase, will be evaluating the intervention that was developed based on the Formative and Pilot Phases. The study population are patients transitioning from the Emergency Department (ED) or hospital to outpatient Medication Assisted Treatment (MAT). The RCT will consist of three arms (1:1:1) with 30 participants in each arm:
The mPeer4Life study tests a peer-based, narrative-driven, mobile phone-assisted intervention to improve linkage to outpatient OUD treatment for patients transitioning from the ED or hospital to MAT. It has three phases: formative, pilot, and trial. The formative phase used interviews with patients, providers, and staff to identify barriers, facilitators, and preferred intervention features. The pilot phase tested usability and helped refine protocols, SOPs, visit schedules, and data forms. A mobile app - the mHealth application and website will provide recovery narratives, peer text support, motivational messages, appointment reminders, medication adherence support, and resources such as housing, employment, self-help groups, safe injection practices, and overdose prevention.
This is the final phase of the study; a randomized controlled trial that will have 30 enrolled participants in each of the three arms:
Arm 1: Peer Navigator + mobile app Arm 2: Peer Navigator only Arm3: Standard of Care referral for MAT linkage.
Participants without phones will receive a study phone with a 3-month prepaid plan. Peer navigators will receive specialized training and support participants in the first two arms. The standard care arm will not receive the app or a peer navigator. The 3-month trial includes two study visits: baseline and exit, during which participants will complete interviews that evaluate current drug use behaviors, medical history, and OUD treatment engagement status.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Enrolled study participants randomized to this arm will proceed with the standard of care referral for MAT linkage at the study site and also be given a) access to the mobile App intervention for use in the three months period from randomization, as the participant transitions from the ED or hospital to outpatient MAT; b) a study-assigned Peer Navigator who will provide support for linkage and engagement in MAT care over the three months.
Behavioral: Mobile phone-assisted intervention · Behavioral: Peer navigator · Behavioral: Standard of care referral for out-patient MAT
Enrolled study participants in this arm will proceed with the standard of care referral for MAT linkage at the study site and also be given a study-assigned Peer Navigator who will provide support for linkage and engagement in the three months period from randomization, as the participant transitions from the ED or hospital to outpatient MAT.
Behavioral: Peer navigator · Behavioral: Standard of care referral for out-patient MAT
Enrolled study participants in this arm will proceed with the standard of care referral for MAT linkage at the study site. The participants will not have access to the mobile Health App intervention and will not be assigned a study Peer Navigator.
Behavioral: Standard of care referral for out-patient MAT
Enrolled study participants transitioning from the ED or hospital to outpatient MAT will be given 3-month access to the use of a mobile phone App developed from information gathered during the formative and pilot phases of the study. The mobile phone app components will include text-based counseling and motivational messaging, appointment reminders, and medication adherence support. It will host resources (including geo-location) to ease access to other social determinants of OUD treatment (MAT) engagement, such as housing, employment, self-help group meeting locations and times, and highlight safe injection and overdose prevention. The intervention will be created to protect confidentiality: the format will not identify the participant as someone with OUD and information will be stored securely.
Study peer navigators will be asked to participate and will undergo extensive training using the curriculum that has been informed by the previous phases. These peer navigators will provide support to patients transitioning from the ED or hospital to outpatient MAT.
Standard of care referral for out-patient MAT care given by the site when patients are transitioning from the ED or inpatient.
MAT initiation at three months after randomization
Study participants who initiate MAT treatment in each arm
Time frame: Up to 12 weeks post randomization
MAT engagement at three months after randomization
Study participants who remain on MAT at 3 months in each arm
Time frame: Up to 12 weeks post randomization
Plan to share: Yes — Only non-confidential data collected to satisfy primary outcomes and study objectives will be shared.
Supporting information: Study protocol
Time frame: After study completion and outcomes analysis is done (Jan 1, 2030)
Access criteria: Public access
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.
Of 464 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 35 months is above that.
Counting every sponsor, half of 495 studies reached it within 29 months; a quarter within 13 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.